NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation models.
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its approved liver disease med Rezdiffra. Madrigal’s thyroid hormone ...
The MarketWatch News Department was not involved in the creation of this content. A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data ...
At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results